NCT06468644View on ClinicalTrials.gov

Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 17, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

chemoradiotherapy （CRT）+sintilimab 1

radiotherapy (50.4Gy/1.8Gy/28f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W

DRUG

CRT+sintilimab 2

radiotherapy (60Gy/2Gy/30f)+chemotherapy (paclitaxel 150mg/m2 D1+cisplatin 25mg/m2 D1-3，Q3W)+Sintilimab (200mg, iv, D1, Q3W) Consolidation therapy: Sintilimab: 200mg, iv, D1, Q3W

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV